Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells

Abaza,Mohamed-Salah   I.; Bahman,Abdul-Majeed; Al-Attiyah,Raja'a

doi:10.3892/ijo.2013.2146

Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells

Authors:
- Mohamed-Salah I. Abaza
- Abdul-Majeed Bahman
- Raja'a Al-Attiyah
View Affiliations

Affiliations: Molecular Biology Program, Department of Biological Sciences, Faculty of Science, Kuwait University, Safat, Kuwait, Department of Microbiology, Faculty of Medicine, Kuwait University, Safat, Kuwait
Published online on: October 22, 2013 https://doi.org/10.3892/ijo.2013.2146
Pages: 105-128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the effectiveness of histone deacetylase inhibitors, proteasome inhibitors and cytotoxic drugs on human cancers, none of these types of treatments by themselves has been sufficient to eradicate the disease. The combination of different modalities may hold enormous potential for eliciting therapeutic results. In the current study, we examined the effects of treatment with the histone deacetylase inhibitor (HDACI) apicidin (APC) in combination with proteasome inhibitors on human colorectal cancer cells. The molecular mechanisms of the combined treatments and their potential to sensitize colorectal cancer cells to chemotherapies were also investigated. Cancer cells were exposed to the agents alone and in combination, and cell growth inhibition was determined by MTT and colony formation assays. HDAC, proteasome and NF-κB activities as well as reactive oxygen species (ROS) were monitored. Cell cycle perturbation and induction of apoptosis were assessed by flow cytometry. The expression of cell cycle/apoptosis- and cytoprotective/stress-related genes was determined by quantitative PCR and EIA, respectively. The potentiation of cancer cell sensitivity to chemotherapies upon APC/PI combination treatment was also studied. The combination of APC and MG132, PI-1 or epoxomicin potently inhibited cancer cell growth, disrupted the cell cycle, induced apoptosis, decreased NF-κB activity and increased ROS production. These events were accompanied by the altered expression of genes associated with the cell cycle, apoptosis and cytoprotection/stress regulation. The combination treatment markedly enhanced the chemosensitivity of colorectal cancer cells (50-3.7x104-fold) in a drug-, APC/PI combination- and colorectal cancer subtype-dependent manner. The results of this study have implications for the development of combinatorial treatments that include HDACIs, PIs and conventional chemotherapeutic drugs, suggesting a potential therapeutic synergy with general applicability to various types of cancers.

View Figures

View References

1.	Heider U, Rademacher J, Lamottke B, et al: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol. 82:440–449. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 25:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Frew AJ, Johnstone RW and Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 280:125–133. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Andrews KT, Walduck A, Kelso MJ, Fairlie DP, Saul A and Parsons PG: Anti-malarial effect of histone deacetylation inhibitors and mammalian tumor cytodifferentiating agents. Int J Parasitol. 30:761–768. 2000. View Article : Google Scholar : PubMed/NCBI
5.	Im JY, Park H, Kang KW, Choi WS and Kim HS: Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and -negative human breast cancer cells. Chem Biol Interact. 172:235–244. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Kim MS, Son MW, Kim WB, Park YI and Moon A: Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 157:23–30. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Kwon SH, Ahn SH, Kim YK, et al: Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem. 277:2073–2080. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Choi JH, Lee JY, Choi AY, et al: Apicidin induces endoplasmic reticulum stress- and mitochondrial dysfunction-associated apoptosis via phospholipase Cγ1- and Ca²⁺-dependent pathway in mouse Neuro-2a. Apoptosis. 17:1340–58. 2012.PubMed/NCBI
9.	Kobayashi H, Tan EM and Fleming SE: Acetylation of histones associated with the p21WAF1/Cip1 gene transcription in human colorectal adenocarcinoma cells. Int J Cancer. 109:207–213. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Xu Y: Regulation of p53 responses by post-translational modifications. Cell Death Differ. 10:400–403. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M and Lin A: Inhibition of JNK activation through NF-κB target gene. Nature. 414:313–317. 2001.
12.	Verma IM, Stevenson JK, Schwartz EM, Van Antwerp D and Miyamoto S: Rel/NF-κB family: intimate tales of association and dissociation. Genes Dev. 9:2723–2735. 1995.
13.	Huang TT, Kudo N, Yoshida M and Miyanoto S: A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes. Proc Natl Acad Sci USA. 97:1014–1019. 2000.
14.	Zandi E, Rothwarf DM, Delhase M, Hayakawa M and Karin M: The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell. 91:243–252. 1997.
15.	Ghosh S, May MJ and Kopp EB: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Ann Rev Immunol. 16:225–260. 1998.
16.	Chen L, Fischle W, Verdin E and Greene WC: Duration of nuclear NF-κB action regulated by reversible acetylation. Science. 293:1653–2657. 2001.
17.	Zhong H, May MJ, Jimi E and Ghosh S: The phosphorylation status of nuclear NF-κB determines its association with CBP/ p300 or HDAC-1. Mol Cell. 9:625–636. 2002.
18.	Sterz J, von Metzler I, Hahne JC, et al: The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs. 17:879–895. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Abaza MS, Al-Safar A, Al-Sawan S and Al-Attiyah R: c-myc anti-sense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumor Biol. 29:287–303. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Abaza MSI: Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells. Exp Ther Med. 1:675–693. 2010.
21.	Lam PK, To EW, Chan ES, Liew CT, Lung IW and King WK: In vitro modulation of head and neck cell growth by human recombinant interferon α and 13-cis-retinoic acid. Br J Biomed Sci. 58:226–229. 2001.
22.	Abaza MSI, Bahman AM, Al-Attiyah RJ and Kollamparambil AM: Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid and proteasome inhibitors: potential mechanisms of action. Tumor Biol. 33:1951–1972. 2012. View Article : Google Scholar
23.	Rosato RR and Grant S: Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs. 13:21–38. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Mayo MW, Denlinger CE, Broad RM, et al: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem. 278:18980–18989. 2003.PubMed/NCBI
25.	Dasmahapatra G, Lembersky D, Son MP, et al: Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 10:1686–1697. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Savita B, Sriram B, Kevin D, et al: The histone deacetylase inhibitor PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NFκB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 15:3354–3365. 2009.PubMed/NCBI
27.	Luu T, Chung C and Somlo G: Combining emerging agents in advanced breast cancer. Oncologist. 16:760–771. 2011. View Article : Google Scholar : PubMed/NCBI
28.	Masdehors P, Omura S, Merle-Béral H, et al: Increased sensitivity of CCL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol. 105:752–757. 1999. View Article : Google Scholar : PubMed/NCBI
29.	Frankland-Searby S and Bhaumik SR: The 26S proteasome complex: An attractive target for cancer therapy. Biochim Biophys Acta. 1825:64–76. 2012.PubMed/NCBI
30.	Adams J: The proteasome: a suitable anti-neoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Nawrocki ST, Bruns CJ, Harbison MT, et al: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 1:1243–1253. 2002.PubMed/NCBI
32.	Yu C, Rahmani M, Conrad D, Subler M, Dent P and Grant S: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl⁺ cells sensitive and resistant to ST1571. Blood. 102:3765–3774. 2003. View Article : Google Scholar : PubMed/NCBI
33.	Vigushin DM and Coomes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 13:1–13. 2002. View Article : Google Scholar
34.	Duan J, Friedman J, Nottingham L, Chen Z, Ara G and Van Waes C: Nuclear factor-κ p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylae inhibitors and novel histone deacetylase inhibitor PZD101. Mol Cancer Ther. 6:37–50. 2007.
35.	Denlinger C, Keller M, Mayo M, Broad RM and Jones DR: Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg. 127:1078–1086. 2004. View Article : Google Scholar : PubMed/NCBI
36.	Tai DI, Tsai SL, Chang YH, et al: Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer. 89:2274–2228. 2000. View Article : Google Scholar : PubMed/NCBI
37.	Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 1:287–299. 2002. View Article : Google Scholar : PubMed/NCBI
38.	Yin L, Laevsky G and Giardina C: Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem. 276:44641–44646. 2001. View Article : Google Scholar : PubMed/NCBI
39.	Jiang Y, Wang Y, Su Z, et al: Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. Mol Med Rep. 3:613–619. 2010.PubMed/NCBI
40.	Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E and Colomer D: The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 107:257–264. 2006. View Article : Google Scholar : PubMed/NCBI
41.	Heider U, von Metzler I, Kaiser M, et al: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome bortezomib in mantle cell lymphoma. Eur J Haematol. 80:133–142. 2008. View Article : Google Scholar : PubMed/NCBI
42.	Ling YH, Liebes L, Zou Y and Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 278:33714–33723. 2003. View Article : Google Scholar : PubMed/NCBI
43.	Pei XY, Dai Y and Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitors bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 10:3839–3852. 2004. View Article : Google Scholar
44.	Pitts TM, Morrow M, Kaufman SA, Tentler JJ and Eckhardt SG: Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cells models. Mol Cancer Ther. 8:342–349. 2009. View Article : Google Scholar : PubMed/NCBI
45.	Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E and Colomer D: The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 109:4441–4449. 2007. View Article : Google Scholar : PubMed/NCBI
46.	Miller C, Ban K, Dujka ME, et al: NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 110:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
47.	Yu C, Friday BB, Yang L, et al: Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro Oncol. 10:309–319. 2007. View Article : Google Scholar
48.	Orlowski RZ: The role of ubiquitin-proteasome pathway in apoptosis. Cell Death Diff. 6:303–331. 1999. View Article : Google Scholar
49.	Buoncervello M, Borghi P, Romagnoli G, et al: Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia. 14:855–867. 2012.
50.	Lawen A: Apoptosis - an introduction. Bioessays. 25:888–896. 2003. View Article : Google Scholar
51.	Lei K, Nimmual A, Zong WX, et al: The Bax subfamily of Bcl2 related proteins is essential for apoptotic signal transduction by c-Jun NH2-terminal kinase. Mol Cell Biol. 22:4929–4942. 2002. View Article : Google Scholar : PubMed/NCBI
52.	Tacchini L, Dansi P, Matteucci E, Bemelli-Zazzera A and Desiderio MA: Influence of proteasome and redox state on heat shock-induced activation of stress kinases, AP-1 and HSF. Biochim Biophy Acta. 1538:76–89. 2001. View Article : Google Scholar : PubMed/NCBI
53.	Gardai SJ, Hildeman DH, Frankel SK, et al: phosphorylation of Bax Ser 184by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 279:21085–21095. 2004. View Article : Google Scholar : PubMed/NCBI
54.	Catley L, Weisberg E, Kiziltepe T, et al: Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 108:3441–3449. 2006.
55.	Baldini E, Gardin G, Giannessi P, et al: A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) study, Italy. Tumori. 83:829–833. 1997.PubMed/NCBI
56.	Hwang JJ, Kim YS, Kim T, et al: A novel histone deacetylase inhibitor, CG2007745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-(XL). Invest New Drugs. 30:1434–1442. 2011. View Article : Google Scholar : PubMed/NCBI
57.	Linares A, Dalenc F, Balaguer P, Boulle N and Gavailles V: Manipulating protein acetylation in breast cancer: a promising approaching in combination with hormonal therapies? J Biomed Biotechnol. 2011:1–15. 2011. View Article : Google Scholar : PubMed/NCBI
58.	Munster PN, Thurn KT, Thomas S, et al: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 104:1828–1835. 2011. View Article : Google Scholar : PubMed/NCBI
59.	O’Connor OA, Heaney ML, Schwartz L, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 24:166–173. 2005.
60.	Vansteenkiste J, Van Cutsem E, Dumez H, et al: Early phase II trial of oral vorinostat in telapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 26:483–488. 2008. View Article : Google Scholar : PubMed/NCBI